The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
Open accessAbstract
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Torre, L. A., Siegel, R. L., & Jemal, A. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-24223-1_1 · Cited by 1,903
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Self-citationPlanchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Camidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Self-citationThe protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Self-citationHida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Self-citationPlanchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Self-citationDrilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ypdi.2015.02.054 · Cited by 353
Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070002 · Cited by 327
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Zou, H. Y., Li, Q., Engstrom, L. D., West, M., Appleman, V., Wong, K. A., McTigue, M., Deng, Y.-L., Liu, W., Brooun, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420785112 · Cited by 267
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02544 · Cited by 265
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Ou, S.-H. I., Jänne, P. A., Bartlett, C. H., Tang, Y., Kim, D.-W., Otterson, G. A., Crinò, L., Selaru, P., Cohen, D. P., Clark, J. W., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt572 · Cited by 219
Self-citationTesting for ROS1 in non-small cell lung cancer: a review with recommendations
Bubendorf, L., Büttner, R., Al-Dayel, F., Dietel, M., Elmberger, G., Kerr, K., López-Ríos, F., Marchetti, A., Öz, B., Pauwels, P., et al. (2016) · Virchows Archiv · doi:10.1007/s00428-016-2000-3 · Cited by 219
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
Thunnissen, E., Bubendorf, L., Dietel, M., Elmberger, G., Kerr, K., Lopez-Rios, F., Moch, H., Olszewski, W., Pauwels, P., Penault-Llorca, F., et al. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1281-4 · Cited by 212
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E. L., Koike, S., Shaw, A. T., Engelman, J. A., & Fujita, N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1385 · Cited by 201
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O., Milia, J., Cabarrou, B., Bluthgen, M.-V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 186
Wynes, M. W., Sholl, L. M., Dietel, M., Schuuring, E., Tsao, M. S., Yatabe, Y., Tubbs, R. R., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000115 · Cited by 164
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Tsao, A. S. (2012) · Yearbook of Oncology · doi:10.1016/j.yonc.2012.06.023 · Cited by 164
Kim, H., Yoo, S.-B., Choe, J.-Y., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C.-T., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 163
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig, S. J., & Shapiro, G. I. (2010) · PubMed · Cited by 155
Kim, H. R., Lim, S., Kim, H. J., Hwang, S., Park, J. K., Shin, E., Bae, M., Ou, S.-H. I., Wang, J., Jewell, S. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt220 · Cited by 128
Wallander, M. L., Geiersbach, K. B., Tripp, S. R., & Layfield, L. J. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0321-oa · Cited by 115
Reck, M., Taylor, F. C., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H. B., Orsini, L. S., & Gralla, R. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.029 · Cited by 111
Weickhardt, A. J., Aisner, D. L., Franklin, W. A., Varella‐Garcia, M., Doebele, R. C., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27913 · Cited by 88
Self-citationComparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
Rogers, T.-M., Russell, P. A., Wright, G. M., Wainer, Z., Pang, J., Henricksen, L. A., Singh, S., Stanislaw, S., Grille, J. G., Roberts, E. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000465 · Cited by 80
von Laffert, M., Warth, A., Penzel, R., Schirmacher, P., Kerr, K. M., Elmberger, G., Schildhaus, H., Büttner, R., López‐Ríos, F., Reu, S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000332 · Cited by 76
Kazandjian, D. G., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S. J., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0101 · Cited by 76
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
Wei, J., van der Wekken, A. J., Saber, A., Terpstra, M. M., Schuuring, E. M. D., Timens, W., Hiltermann, T. J. N., Groen, H. J. M., den Berg, A. V., & Kok, K. (2018) · Cancers · doi:10.3390/cancers10010010 · Cited by 55
Zhou, J., Zhao, J., Sun, K., Wang, B., Wang, L., Chen, X., Zheng, J., You, Q., Wang, X., Ding, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092828 · Cited by 48
Browning, E. T., Weickhardt, A. J., & Camidge, D. R. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827a892c · Cited by 36
West, H., Oxnard, G. R., & Doebele, R. C. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e272 · Cited by 24
Cited by
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 679
Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 310
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Metadata
- Authors
- Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M., Govindan, R., Gubens, M. A., Hennon, M., Horn, L., Lackner, R. P., Lanuti, M., Leal, T. A., Lilenbaum, R., Lin, J., Loo, B. W., Martins, R., Otterson, G. A., Patel, S. P., Reckamp, K., Riely, G. J., Schild, S. E., Shapiro, T. A., Stevenson, J., Swanson, S. J., Tauer, K., Yang, S. C., Gregory, K., & Hughes, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2018-07
- Volume
- 16
- Issue
- 7
- Pages
- 807-821
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2917696006
- Cited by
- 463
- References
- 55
- FWCI
- 55.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.